For example, a recent synthetic lethality screen suggested a mechanistic explanation of mutual exclusivity between CCNE1 amplification and BRCA1/2 mutation, and further showed the sensitivity of CCNE1-amplified tumor cells to bortezomib [4]. This evidence concerns the gene CCNE1 and neoplasm.